Hyderabad: A single-dose tetravalent dengue vaccine is entering clinical trials under the Indian Council of Medical Research (ICMR), with AIIMS Bibinagar in Telangana selected as one of the trial sites.
ICMR on Tuesday announced the launch of trials for the live attenuated recombinant lyophilised vaccine branded as ‘DengAal’. The study will be conducted in collaboration with JSS Medical College in Mysuru and Bangalore Medical College.
More than 10,000 healthy volunteers have enrolled, with 70% already vaccinated in the initial trial phase. According to agency, the remaining 30% will be administered the dose in a phased rollout.
AIIMS Bibinagar joins national dengue vaccine initiative
The vaccine trial at AIIMS Bibinagar forms part of a broader national strategy to combat dengue with a single-dose immunisation model. This is aimed at wide public coverage.
